Is Trident Texofab overvalued or undervalued?

As of 17 November 2025, the valuation grade for Trident Texofab moved from very expensive to expensive. The company is currently considered overvalued based on its high valuation ratios. The PE ratio stands at 170.80, while the EV to EBITDA ratio is 65.33, and the PEG ratio is 18.53, all significantly above typical industry benchmarks.
In comparison to its peers, Trident Texofab's valuation appears elevated; for instance, Elitecon International has a PE ratio of 294.38, indicating extreme valuation, while PTC India, which is rated very attractive, has a PE of just 7.56. Despite the company's impressive stock performance, with a year-to-date return of 100.65% compared to the Sensex's 8.72%, the current valuation metrics suggest that Trident Texofab is overvalued in the garments and apparel industry.